<DOC>
	<DOCNO>NCT02813148</DOCNO>
	<brief_summary>This post-authorization observational safety study determines characteristic patient prescribe naloxegol time first prescription treatment pattern naloxegol follow-up United Kingdom ( UK ) , Norway , Sweden , Germany .</brief_summary>
	<brief_title>Naloxegol Drug Utilization PASS</brief_title>
	<detailed_description>The overall research question study : 1 ) What demographic , clinical , treatment characteristic ( include dose ) baseline patient prescribe naloxegol real-world practice ( include use naloxegol non-indicated population ) ? 2 ) What treatment pattern naloxegol utilization follow-up ? Primary objective : 1 . To describe characteristic patient prescribe naloxegol time first prescription ( demographic , targeted comorbidities , target comedications , provider characteristic , indication characteristic ) . 2 . To describe follow treatment pattern : - Discontinuation naloxegol ( permanently observation period ) - Switching naloxegol drug ( ) potentially used patient opioid induced constipation ( OIC ) - Prescription drug ( ) potentially used patient OIC period naloxegol prescribe ( augmentation ) - Restart prescription naloxegol ( temporary discontinuation treatment holiday ) - Continuous treatment naloxegol study period - Change dose Exploratory objective : 1 . To identify predictor length naloxegol use</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>1 . The patient least 1 prescription naloxegol his/her medical record anytime study period . 2 . The patient least 12 month computerize record prior first prescription naloxegol ( index date ) No exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>